📅 EVENT: Belite Bio (🇺🇸Nasdaq: BLTE) will be presenting at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2024) on May 5, 2024 from 3:45 PM to 4:00 PM PT in Seattle, WA. More Info: https://lnkd.in/gww6gWCu
Belite Bio’s Post
More Relevant Posts
-
OpRegen®(RG6501) Preclinical Engraftment Results to be Presented at the 2024 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. Read here: https://bit.ly/3Tu4voC @Retina Today #ReplaceandRestore #Retina
To view or add a comment, sign in
-
🌟 At the forefront of ophthalmology: Dr. David Eichenbaum shares compelling results from a Phase IIB clinical trial at Retina World Congress. The study highlights Sozinibercept’s potential when combined with Ranibizumab, showing significant improvements in visual acuity for patients with specific types of macular lesions. This promising advancement could redefine treatment standards for neovascular macular degeneration by targeting both VEGF-A and additional pathways. #RWC2024 #OphthalmologyInnovation #ClinicalTrials Genentech Opthea RIWC24: Retina International World Congress 2024
To view or add a comment, sign in
-
Thanks to curated #RWD, we're gaining insights into cataracts, which are the leading cause of vision loss in the U.S. Learn how our recent partnership with the FDA and the American Academy of Ophthalmology led to major findings surrounding #IOL use among young patients with cataracts: https://hubs.la/Q02zhLTz0
To view or add a comment, sign in
-
Great news! We recorded the interactive session, so you can still benefit from all the insights we gained. 🎉 📽️ Watch the replay: https://bit.ly/3S3h2y3
🚀 Last week we held a very interesting webinar on #IBEX multiplex #immunohistochemistry with Dr. Amar TAMRA, PhD from Fluigent & Dr. Colin Chu from the UCL Institute of Ophthalmology, UK. 🔬 The good news is that we recorded the interactive session, so you can still take advantage of everything we learned. 🎉 📽️ Wtach the replay: https://bit.ly/3S3h2y3 Join us on Linkedin or on our Newsletter to be the first to know about our upcoming webinars this year. 👉https://bit.ly/3VY4XLS We look forward to seeing you next time! 👋 #Microfluidics hashtag#IBEX hashtag#Webinar hashtag#BiotechInnovation hashtag#NIH
To view or add a comment, sign in
-
LAST CALL: Urgent Extension for Abstract Submission! Time is running out! We're extending the abstract submission for OSWI's 35th Congress, but the window is closing FAST. You now have until January 14, 2024, @ midnight! This is YOUR moment to make a mark on the global ophthalmology stage. Don't let this opportunity slip away – submit your abstract NOW to be part of the most thrilling event in the field! Urgency is in the air! Act NOW and be a pivotal force in shaping the future of ophthalmology! The clock is ticking loudly! #OSWI35thCongress #LastCallAbstracts #OphthalmologyInnovation
To view or add a comment, sign in
-
👀 Geographic atrophy (GA) is one of the characteristics of advanced age-related macular degeneration (AMD) and can cause vision loss, even legal blindness. Yet, treatment options for GA or its progression remain limited. This NEI research investigated minocycline's potential to slow vision loss and halt GA expansion in AMD patients. Our VeriSee AMD, a TFDA-approved medical AI, makes early screening for AMD and early access to ophthalmic care possible. Together, we can improve public health of eye care! #AMD #GeographicAtrophy #EyeHealth #NEI #AcerMedical #VeriSeeAMD
Tiarnan Keenan and colleagues at the National Eye Institute (NEI) released results of a phase II clinical study looking at the drug minocycline, an antibiotic that also decreases inflammation, and its effects in slowing vision loss or expansion of geographic atrophy in people with age-related macular degeneration (AMD). Check the JAMA Ophthalmology paper: https://bit.ly/4a6aJAI
To view or add a comment, sign in
-
The Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting gave us the opportunity to highlight our most recent research on real-life data which can be utilized to assess the impact of light through dynamic ophthalmic filters, including the newly introduced Transitions Gen S lenses (Transitions Optical), as detailed in our poster presentation. Real life data collection has opened new opportunities for evaluating the light effects of new ophthalmic filters, from passive (clear/sun) to dynamic lenses. Here we propose to use existing recorded light exposure and wearing behaviors data from real-life to simulate retrospectively, the evolution in time of a new Transitions Gen S, and value its seamless protective and dynamic capability. Aurélie Le Cain, Ph.D, Simon Weinberger, Anne Catherine Scherlen, Coralie Barrau
To view or add a comment, sign in
-
Cool stuff for eCOA and Imaging in ophthalmology research! 📣 Sign up for our July 11 webinar! Our experts Todd Rudo, Amit Vasanji, and Kelly Dumais will explore strategies to enhance patient access and precision analysis using artificial intelligence (#AI) in ophthalmology clinical trials. We’ll dive into: ▫️Vendor-agnostic, multi-modality platforms ▫️AI-enabled workflows ▫️Best practices for eCOA implementation in various trial settings ➡️ Register now and don’t miss the opportunity to learn how AI transforms ophthalmology clinical trials: https://lnkd.in/eYh52nv7 #artificialintelligence #clinicaltrials #ophthalmology
To view or add a comment, sign in
-
As a passionate advocate for cutting-edge medical technology, I'm thrilled by the performance of RadiusXR, a game-changer in the field of visual field testing. 💡 Let's dive into the technical differentiators: 1️⃣ Precision Engineering: Unlike other virtual reality perimeters (VRPs) that repurpose consumer-grade gaming headsets, RadiusXR is meticulously designed and manufactured specifically for ophthalmology. This ensures optimal performance and reliability, giving clinicians the assurance they need in their diagnostic tools. 🔬 2️⃣ Unparalleled Accuracy: Our NOVA Clinical Trial has demonstrated a remarkable 0.94 correlation in mean deviation and statistical non-inferiority for glaucoma staging compared to traditional methods. This level of accuracy is a game-changer in diagnosing and managing ocular conditions, empowering clinicians with actionable insights to improve patient outcomes. 📊Read the peer-reviewed publication in the Journal of Translational Vision Science and Technology published by the Association for Research in Vision and Ophthalmology (ARVO). 3️⃣ Photopic Range Measurement: One of our key differentiators is our ability to measure vision within the photopic range, aligning perfectly with existing visual field platforms' standards. This ensures consistent clinical training and facilitates comparison to patients' prior examinations, ultimately enhancing outcomes. 🌟 4️⃣ Innovation in Action: RadiusXR is not just pushing boundaries but redefining them. This technology combines spatial computing with precision engineering to deliver unparalleled accuracy and reliability. From glaucoma staging to monitoring disease progression, RadiusXR is paving the way for a brighter future in ocular health. #RadiusXR #Innovation #OcularHealth #MedicalTechnology #VisionaryTech
🎉 Big News Alert! 🎉 Thrilled to announce that RadiusXR's 'NOVA' Clinical Trial has been published in Association for Research in Vision and Ophthalmology (ARVO)'s Translational and Vision Science journal! 📚 Our innovative approach highlights statistical non-inferiority to current clinical standards for sensitivities at individual test locations, glaucoma staging using Medicare definitions and an exceptionally high correlation of 0.94 in mean deviation. Plus, our technology measures vision within the photopic range for consistent clinical training. 🌟 Leading ophthalmologists are hailing this as a game-changer! 🚀 Check out the full article https://buff.ly/3VnICso #RadiusXR #NOVAClinicalTrial #Innovation #OcularHealth #VisionScience
To view or add a comment, sign in
-
Relationship Manager @ IQVIA MedTech | Clinical Research, Real-World Evidence & Regulatory Consulting
Breaking barriers in glaucoma treatment! Celanese Corporation and Glaukos Corporation join forces to introduce iDose(R) TR, a game-changer in sustained drug release for better patient outcomes. Discover how this innovative solution is reshaping ophthalmology! #GlaucomaInnovation #CelaneseImpact #MedicalAdvancements #EyeCare #TidbitThursday
To view or add a comment, sign in
1,062 followers